Wade Aubry, MD
Endocrinology, Diabetes & Metabolism · San Francisco, CANPI 1447265814
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $72,693 of the $79,046 with a category attached, or 92.0%. 9 manufacturers reported payments, led by Greenwich Biosciences, Inc. at 47.8% of the total. Reporting peaked in 2020 at $28,050 and has fallen 90.2% since, to $2,750 in 2023. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $1838.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Greenwich Biosciences, Inc.$38K
- EMD Serono, Inc.$12K
- Vertex$7K
- AbbVie$6K
- Novartis$5K
- Pear Therapeutics (US), Inc.$4K
- plus $7K from 3 others
What the payments were for
- Consulting fees$72,69392%
- Speaking & faculty fees$3,4844%
- Travel & lodging$2,4343%
- Food & beverage$4351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Greenwich Biosciences, Inc. | 14 | $37,750 |
| EMD Serono, Inc. | 5 | $12,365 |
| Vertex | 10 | $6,810 |
| AbbVie(2 entities) | 5 | $6,312 |
| Novartis | 5 | $4,558 |
| Pear Therapeutics (US), Inc. | 1 | $4,200 |
| Ferring Pharmaceuticals Inc. | 1 | $2,750 |
| Jazz Pharmaceuticals Inc. | 1 | $2,500 |
| Endogastric Solutions, Inc | 1 | $1,800 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,046 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 22 | $6,553 |
| Bupropion XlBupropion Hcl | 18 | $543 |
| Lisinopril | 14 | $283 |
| Lovastatin | 14 | $247 |
| Losartan Potassium | 14 | $215 |
| Levothyroxine Sodium | 17 | $170 |
| ClopidogrelClopidogrel Bisulfate | 12 | $85 |
| Metoprolol Succinate | 14 | $77 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in San Francisco
- Cheng Yang TuanSan Francisco$568K
- Lewis BlevinsSan Francisco$166K
- Marc HellersteinSan Francisco$56K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.